Differences between revisions 1 and 5 (spanning 4 versions)
Revision 1 as of 2007-11-06 09:53:10
Size: 382
Editor: GaryBader
Comment:
Revision 5 as of 2007-11-06 11:14:19
Size: 1948
Editor: GaryBader
Comment:
Deletions are marked like this. Additions are marked like this.
Line 5: Line 5:
 * Testing as a task – assign different parts of Cytoscape to developers for testing - offline  * Testing as a task – assign different parts of Cytoscape to developers for testing - offline. How can we get more developers and users involved in testing.
 * No 2.7 will be released (decision could be revisited), but we will work on 2.6 and add documentation, bug fixes, small features, new core plugins in maintenance releases. Goal: smooth over most of the workflows.
Line 12: Line 13:
 * Plugin developers have issues with too frequent releases
 * Feature suggestion from Carlo: action tracing - how did I get to this result?
 * Smoothing workflows may take a while to do
 * Break

 * 3.0 overview
 * Cytoscape problems - things that the RFCs address
 * People would like to have a stable plugin API and also access to internal classes
 * Going through all of the RFCs
  * Line types - can't we support some extra custom line types for 2.6.x? No, the renderer doesn't support some line types. It would need low level changes.

 * RFC 52: Event Handling System
  * Mouse events are clobbered - major issue is that multiple plugins want to access mouse related events. This could be solved by having Cytoscape mediate the events. There may be a use case for plugins to only listen to events for specific networks e.g. for networks they create.
   * Decision: Only allow plugins to listen to Cytoscape events, not lower level events, to allow arbitration, prevent conflicts.
   * Decision: A module should define its event interface - the events it listens for and produces
   * Decision: Plugin registers interest in specific events within the scope of user edits with some manager system.
   * Task: event inventory
   * Task: what events do we need?

Day 1 notes

Decisions:

  • Cytoscape release: Mid jan, feb.1 as goal for release
  • Testing as a task – assign different parts of Cytoscape to developers for testing - offline. How can we get more developers and users involved in testing.
  • No 2.7 will be released (decision could be revisited), but we will work on 2.6 and add documentation, bug fixes, small features, new core plugins in maintenance releases. Goal: smooth over most of the workflows.

Discussion threads:

  • Introductions (everyone)
  • Cytoscape 2.6 development status update
  • Testing - how to increase coverage and get better unit tests
  • Should we have a 2.7 release?
  • Plugin developers have issues with too frequent releases
  • Feature suggestion from Carlo: action tracing - how did I get to this result?
  • Smoothing workflows may take a while to do
  • Break
  • 3.0 overview
  • Cytoscape problems - things that the RFCs address
  • People would like to have a stable plugin API and also access to internal classes
  • Going through all of the RFCs
    • Line types - can't we support some extra custom line types for 2.6.x? No, the renderer doesn't support some line types. It would need low level changes.
  • RFC 52: Event Handling System
    • Mouse events are clobbered - major issue is that multiple plugins want to access mouse related events. This could be solved by having Cytoscape mediate the events. There may be a use case for plugins to only listen to events for specific networks e.g. for networks they create.
      • Decision: Only allow plugins to listen to Cytoscape events, not lower level events, to allow arbitration, prevent conflicts.
      • Decision: A module should define its event interface - the events it listens for and produces
      • Decision: Plugin registers interest in specific events within the scope of user edits with some manager system.
      • Task: event inventory
      • Task: what events do we need?

CytoscapeRetreat2007/HackathonNotes (last edited 2009-02-12 01:03:11 by localhost)

Funding for Cytoscape is provided by a federal grant from the U.S. National Institute of General Medical Sciences (NIGMS) of the Na tional Institutes of Health (NIH) under award number GM070743-01. Corporate funding is provided through a contract from Unilever PLC.

MoinMoin Appliance - Powered by TurnKey Linux